Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Stockwatch: Mistaken Acquisitions Dim Earnings Season

Executive Summary

Fourth-quarter earnings reports from J&J, Novartis, AbbVie and Biogen all missed on sales but more worryingly, lower sales from some recent acquisitions contributed to the missed expectations. The time from child star to problem child seems to be shorter than I remember.

You may also be interested in...



Can Slow Selling Heart Drug Entresto Perk Up In 2017? Novartis Hopes So

Sales of Novartis' Entresto have been painfully slow and missed their 2016 target of $200m – but the big pharma hopes the heart failure drug's sales momentum will take off next year and it remains confident the first-in-class therapy will eventually reach peak annual sales of around $5bn.

Fresh From The White House, J&J's Gorsky Talks Policy, Drug Pricing

CEO pledges transparency and responsible pricing of J&J drugs during the company’s earnings call, while outlining its goals for US health care and tax reform. Fourth quarter performance was unspectacular, although J&J's oncology and immunology portfolios showed sales growth.

Emicizumab Data Has Shire And Novo Looking Over Their Shoulders

Positive data from the HAVEN 1 Phase III study of Genentech's emicizumab put pressure on the hemophilia franchises of both Shire and Novo Nordisk.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM001644

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel